Angiogenic Biomarkers in Juvenile Idiopathic Arthritis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood sample, Joint puncture.
- Who it may be relevant to
- Registry conditions: Juvenile Idiopathic Arthritis (JIA). Basic parameters: from 16 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis
Overview
The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.
Detailed description
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic inflammatory rheumatic diseases beginning before the age of 16. The most common pediatric rheumatologic disease. JIA is the most common pediatric rheumatologic disease. Apart from clinical features and the biological inflammatory syndrome, no predictive parameter for the severity of JIA, especially polyarticular JIA, has been identified. The team has been interested in the prognosis of RA for many years. Thus, the investigators have conducted various studies in search of biological parameters associated with the joint prognosis of RA patients, which allowed the investigator to discover the interest of angiogenic and inflammatory biomarkers such as semaphorins and CCN1 protein. This has been demonstrated in vitro but also in vivo from sera of RA patients. These markers are associated with activity and structural damage in RA.
The project aims to study the interest of these same angiogenic biomarkers in the serum of JIA patients in order to establish whether, as in RA, they are also associated with disease severity.
Interventions
- Biological Blood sample
Addtional tube of blood needed for follow up of patients - Biological Joint puncture
Joint puncture if needed according to routine care of the patients
Primary outcome measures
- Dosage of angiogenic markers [Time frame: 5 years]
- Dosage of angiogenic markers [Time frame: 5 years]
- Dosage of inflammatory markers by ELISA method [Time frame: 5 years]
- Dosage of inflammatory markers by ELISA method [Time frame: 5 years]
Secondary outcome measures (5)
- Questionnaires [Time frame: 5 years]
- Collection of treatments received [Time frame: 5 years]
- Structural damage determined by x-rays [Time frame: 5 years]
- Angiogenic biomarkers [Time frame: At inclusion]
- Inflammatory biomarkers [Time frame: At inclusion]
Eligibility criteria
Inclusion criteria
- Greater than or equal to 16 years-old
- Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital
- No-opposition to the research
- Patient with health insurance
- Mastery of the French language
Exclusion criteria
- Patient under curatorship or guardianship
- Patient receiving french state medical aid
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Rheumatology Department, Cochin Hospital — Paris
Identifiers
NCT: NCT05534347 · APHP220364 · 2022-A00468-35